Cilostazol controlled-release - Korea United Pharma

Drug Profile

Cilostazol controlled-release - Korea United Pharma

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Korea United Pharm Inc
  • Class Antiplatelets; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Arterial occlusive disorders; Intermittent claudication

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Arterial-occlusive-disorders(In volunteers) in South Korea (PO, Controlled release)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Intermittent-claudication(In volunteers) in South Korea (PO, Controlled release)
  • 09 Mar 2013 Phase-I clinical trials in Arterial occlusive disorders (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top